Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational services; and biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. Further, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

Revenue projections:

Revenue projections for LAURUSLABS
Revenue projections for LAURUSLABS

LAURUSLABS is projected to see a decline in revenue compared to last year, which could lead to investor caution. A drop in earnings is often viewed as a negative signal for profitability, making it more difficult for the company to maintain investor confidence in its financial health.

Financial Ratios:

currentRatio 0.000000
forwardPE 59.331913
debtToEquity 46.369000
earningsGrowth 0.194000
revenueGrowth 0.060000
grossMargins 0.570230
operatingMargins 0.220370
trailingEps 15.630000
forwardEps 18.648480

With LAURUSLABS's forward PE being too high, further price appreciation may be limited, and a correction could occur. This valuation metric signals potential overvaluation, and investors should analyze it carefully along with other fundamentals to make informed decisions.
With positive gross and operating margins, Laurus Labs Limited's profitability is evident. These metrics suggest the company is efficiently managing its expenses while maintaining strong revenue, highlighting a solid financial foundation.
LAURUSLABS's forward EPS surpassing its trailing EPS signals that the company is anticipated to be more profitable this year than last. This growth expectation highlights LAURUSLABS's potential for increased earnings and a stronger financial performance in the upcoming year.

Price projections:

Price projections for LAURUSLABS
Price projections for LAURUSLABS

Laurus Labs Limited's price projections have gradually increased over time, indicating that analysts are becoming more optimistic about the company's prospects. This suggests confidence in Laurus Labs Limited's ability to achieve future growth.

Recommendation changes over time:

Recommendations trend for LAURUSLABS
Recommendations trend for LAURUSLABS


LAURUSLABS has received a favorable buy bias from analysts recently, positioning it as a solid investment opportunity. This sentiment may attract more investors, who view LAURUSLABS as a stable option to park their money and potentially benefit from the company's continued growth and profitability.